• Merck will present new HIV treatment and prevention pipeline data at the International AIDS Conference in Rio de Janeiro on July 26-31, 2026.
• Late-breaker sessions are set to feature Phase 3 week-48 results for once-weekly islatravir/lenacapavir switch regimens versus daily standard-of-care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607150700BIZWIRE_USPR_____20260715_BW827319) on July 15, 2026, and is solely responsible for the information contained therein.